Akademik Veri Yönetim Sistemi
29th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), Amsterdam, Hollanda, 13 - 16 Nisan 2019, ss.656, (Özet Bildiri)
Background:The use of immunoglobulins in children is known to increase over theyears. In this study, it was
aimed to investigatethe drug utilization characteristics in immunoglobulin-containing prescriptions written by
pediatricians.
Materials/methods: In this retrospectivestudy, weevaluated all paediatric (age <18 years) prescriptions
registered to the Prescription Information System (PIS) of Turkish Medicines and Medical Devices Agency by
paediatricians or subspecialists of paediatrics in Turkey in Year 2015.The drugs in the prescriptions wereclassified
according to the Anatomical Therapeutic Chemical (ATC) system and those prescriptions containing medications
with J06 code(immuneserums and immunoglobulins) wereanalysed in detail.
Results: A total of 18,580,508 drugs werefound to be prescribed by pediatricians in 2015,as registered in PIS. In
these prescriptions, the main subgroup of “J -anti-infectives for systemic use” constituted 22.9% (n=4,246,540) of
all the drugs. At ATC-2 level, 6,292 (0.03%) drugs belonged to the“J06 code- immuneserums and
immunoglobulins”,all of which wereimmunoglobulins (J06B) at the ATC-3 level.The most commonly prescribed
drugs in children were detected as palivizumab (n=4,233) and “human-derived intravenous immunoglobulins”
(n=2,031), which werefollowed by “hepatitis B immunoglobulins” (n=24), “anti-D (rh) immunoglobulins” (n=3),
and “tetanus immunoglobulins” (n=1).
Conclusions: It is observed that pediatricians prescribed palivizumab by >2-fold often than other
immunoglobulins during thestudy period according to PIS data. Considering theindication of this drug, it is
understood that pediatricians preferred J06B-immunoglobulins rather for prophylaxis of respiratory syncytial
virus disease.